Vivani Medical Inc (VANI) 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with...

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or overweight...

Form 8-K - Current report

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active...

Form 8-K - Current report

Form 8-K - Current report

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse...